Immune treatment in COVID-19.
Rev Esp Quimioter
; 35 Suppl 1: 59-63, 2022 Apr.
Article
en En
| MEDLINE
| ID: mdl-35488829
ABSTRACT
Current immune treatment directed to avoid viral replication relies mainly in convalescent plasma and monoclonal antibodies (mAbs). No clinical benefit for convalescent plasma has been reported in a meta-analysis and systematic review compared to standard of care. MAbs are recombinant proteins capable to bind with SARS-CoV-2 preventing its entrance into cells. Several mAbs have shown reduction in viral load and/or progression of the disease such as casirivimab-imdevimab, bamlanivimab-etesevimab and sotrovimab. After the apparition of Omicron variant, it has been reported that sotrovimab retained its activity whereas the other two combinations exhibited loss of neutralizing activity. Several aspects as the target population, timing and doses, serological patient status and evolution of variants still require attention, monitorization and further studies for knowledge gaps.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Glicoproteína de la Espiga del Coronavirus
/
COVID-19
/
Tratamiento Farmacológico de COVID-19
Límite:
Humans
Idioma:
En
Revista:
Rev Esp Quimioter
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2022
Tipo del documento:
Article